![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
Melanoma
April 19, 2023
Summaries of recently published ECOG-ACRIN research results
October 13, 2022
Summaries of recently published ECOG-ACRIN research results
October 13, 2022
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
April 15, 2022
Congress creates a new health care research agency; NCI-MATCH continues to offer treatment options; ECOG-ACRIN plans for first in-person Group Meeting since 2019
April 15, 2022
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
November 16, 2021
Practice-changing trial results in melanoma; Group and committee leadership updates; remembering a dear colleague and friend
November 16, 2021
The phase 3 DREAMseq clinical trial provides strong evidence for starting treatment with combination immunotherapy then giving targeted therapy if the disease progresses in patients with BRAF V600 mutant metastatic melanoma
November 16, 2021
This phase II randomized controlled trial is evaluating the effect of adding hydroxychloroquine to treatment with dabrafenib and trametinib in patients with advanced BRAF mutant melanoma
March 31, 2021
This phase II study, led by Dr. Ahmad Tarhini, is testing neoadjuvant treatment with pembrolizumab alone versus pembrolizumab and an investigational drug called CMP-001
May 29, 2020
What we know about COVID-19; remembering Valerie Guild; spotlight on Indiana University's Melvin and Bren Simon Comprehensive Cancer Center
April 15, 2020
A single-arm phase II trial evaluating the effectiveness of treatment before surgery with encorafenib and binimetinib